The long-term objective of the research outlined in this application is to better understand the role of drug interactions in the rare, but potentially fatal hepatotoxicity caused by valproic acid (VPA), and to account for the unexplained observation that recent febrile illness represents a predisposing factor in VPA-mediated liver injury. Particular emphasis will be placed on the involvement of tumor necrosis factor (TNF), an endogeneous cytokine released in response to bacterial and viral infections, in depleting hepatic stores of glutathione (GSH) and rendering liver tissue more vulnerable to drug-induced injury. The hypothesis to be tested is that VPA and hepatotoxic VPA metabolites act synergistically with other antiepileptic drugs and TNF to cause oxidative stress and liver damage. This hypothesis will be tested by a number of in vitro and in vivo studies, the specific aims of which are as follows: (A) To develop improved methodology for the analysis of GSH and GSSG in biological specimens. (B)1. To demonstrate that liver injury results from the treatment of animals with a combination of VPA, phenytoin/carbamazepine and TNF at non-hepatotoxic doses of each component. (B)2. To demonstrate that the liver injury in (B)1 is associated with depletion of GSH. (B)3. To determine whether treatment with NAC (i) protects against the liver injury in (B)1 and (ii) attenuates the depletion of GSH in (B)2. (C)1-3. In parallel to Aims (B)1-3, to demonstrate that a similar phenomenon occurs with delta4-VPA (a potent hepatotoxic metabolite of VPA). (D)1. To investigate the mechanism by which VPA inhibits GSSG reductase. (D)2. To investigate the role of a delta2(E),4-VPA-CoA as a reactive metabolite of delta4-VPA in mitochondria. (D)3. To compare the respective abilities of delta4-VPA and its non-hepatotoxic isomer delta2(E)-VAP to deplete GSH and cause oxidative stress. The experimental approach will utilize the rat as an animal model for in vivo studies, and will employ both intact hepatocytes and cell-free preparations from rat liver for in vitro work. New analytical techniques, based on electrospray mass spectrometry, will be developed to assess changes in GSH homeostasis, and to investigate the production of chemically-reactive, potentially toxic, CoA thioester metabolites of VPA in liver mitochondria. The proposed studies on the involvement of TNF as an endogeneous mediator of drug-induced liver damage is novel feature of the proposed research, and should provide important information on the role of this cytokine in exacerbating oxidative stress caused by foreign compounds. The project will also focus on the toxicological consequences of the interplay between fatty acid and xenobiotic metabolism. Collectively, these studies are intended to provide a basic understanding of the role of drug interactions and prodromal illness in VPA liver toxicity, which should lead to the development of safer, improved therapy with VPA and related antiepileptics.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM032165-14
Application #
5212093
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1996
Total Cost
Indirect Cost
Wong, Timothy; Wang, Zhican; Chapron, Brian D et al. (2018) Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D3-3-O-Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metab Dispos 46:367-379
Shirasaka, Y; Chaudhry, A S; McDonald, M et al. (2016) Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 16:375-87
Manoj, Kelath Murali; Parashar, Abhinav; Gade, Sudeep K et al. (2016) Functioning of Microsomal Cytochrome P450s: Murburn Concept Explains the Metabolism of Xenobiotics in Hepatocytes. Front Pharmacol 7:161
Stamper, Brendan D; Garcia, Michael L; Nguyen, Duy Q et al. (2015) p53 Contributes to Differentiating Gene Expression Following Exposure to Acetaminophen and Its Less Hepatotoxic Regioisomer Both In Vitro and In Vivo. Gene Regul Syst Bio 9:1-14
McDonald, Matthew G; Au, Nicholas T; Rettie, Allan E (2015) P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms. Drug Metab Dispos 43:1661-9
Chaudhry, Amarjit S; Prasad, Bhagwat; Shirasaka, Yoshiyuki et al. (2015) The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug Metab Dispos 43:1226-35
Liu, Li; Collier, Ann C; Link, Jeanne M et al. (2015) Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. Drug Metab Dispos 43:1795-804
Ho, Han Kiat; Chan, James Chun Yip; Hardy, Klarissa D et al. (2015) Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib. Drug Metab Rev 47:21-8
Chapron, Brian; Risler, Linda; Phillips, Brian et al. (2015) Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes. J Pharm Pharm Sci 18:101-11
Kaspera, RĂ¼diger; Kirby, Brian J; Sahele, Tariku et al. (2014) Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol 91:109-18

Showing the most recent 10 out of 361 publications